Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study

BACKGROUND: To evaluate the long-term efficacy, safety and immunogenicity of continuing LBEC0101; the etanercept (ETN) biosimilar; or switching from the ETN reference product (RP) to LBEC0101 in patients with rheumatoid arthritis (RA). METHODS: This multicentre, single-arm, open-label extension stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Min-Chan, Matsuno, Hiroaki, Kim, Jinseok, Park, Sung-Hwan, Lee, Sang-Heon, Park, Yong-Beom, Lee, Yun Jong, Lee, Sang-Il, Park, Won, Sheen, Dong Hyuk, Choe, Jung-Yoon, Choi, Chan-Bum, Hong, Seung-Jae, Suh, Chang-Hee, Lee, Shin-Seok, Cha, Hoon-Suk, Yoo, Bin, Hur, Jin-Wuk, Kim, Geun-Tae, Yoo, Wan-Hee, Baek, Han Joo, Shin, Kichul, Shim, Seung Cheol, Yang, Hyung-In, Kim, Hyun Ah, Park, Kyung-Su, Choi, In Ah, Lee, Jisoo, Tomomitsu, Masato, Shin, Seonghye, Lee, Jiyoon, Song, Yeong Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528252/
https://www.ncbi.nlm.nih.gov/pubmed/31113455
http://dx.doi.org/10.1186/s13075-019-1910-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528252/
https://www.ncbi.nlm.nih.gov/pubmed/31113455
http://dx.doi.org/10.1186/s13075-019-1910-2

Ejemplares similares